Page last updated: 2024-12-07
sarisan
Description
sarisan: isolated from Heteromorpha trifoliata; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|
| Heteromorpha | genus | [no description available] | Apiaceae | A large plant family in the order Apiales, also known as Umbelliferae. Most are aromatic herbs with alternate, feather-divided leaves that are sheathed at the base. The flowers often form a conspicuous flat-topped umbel. Each small individual flower is usually bisexual, with five sepals, five petals, and an enlarged disk at the base of the style. The fruits are ridged and are composed of two parts that split open at maturity.[MeSH] |
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 95289 |
| CHEBI ID | 9031 |
| SCHEMBL ID | 14552371 |
| MeSH ID | M0157410 |
Synonyms (37)
| Synonym |
|---|
| 1,3-benzodioxole, 5-methoxy-6-(2-propenyl)- |
| benzene, 1-allyl-2-methoxy-4,5-methylenedioxy |
| nsc-44848 |
| nsc44848 |
| nsc-27868 |
| nsc27868 |
| 18607-93-7 |
| sarisan |
| AC1L3TZ6 , |
| 5-methoxy-6-prop-2-enyl-1,3-benzodioxole |
| AC1Q6ZU6 , |
| nsc 27868 |
| unii-cwl14zq19x |
| 1-allyl-2-methoxy-4,5-(methylenedioxy)benzene |
| cwl14zq19x , |
| ai3-31217 |
| asaricin |
| CHEBI:9031 |
| 1-allyl-2-methoxy-4,5-methylenedioxybenzene |
| SCHEMBL14552371 |
| FYRHTIWFKXZWAD-UHFFFAOYSA-N |
| 4-methoxysafrole |
| 5-allyl-6-methoxy-1,3-benzodioxole |
| DTXSID10171851 |
| 2-allyl-4,5-methylenedioxyanisole |
| benzene, 1-allyl-2-methoxy-4,5-(methylenedioxy)- |
| 5-methoxy-6-(2-propen-1-yl)-1,3-benzodioxole |
| 1,3-benzodioxole, 5-methoxy-6-(2-propen-1-yl)- |
| 5-methoxy-6-(2'-propenyl)benzodioxole |
| Q27108222 |
| 5-allyl-6-methoxybenzo[d][1,3]dioxole |
| STARBLD0000864 |
| 5-methoxy-6-(2-propenyl)-1,3-benzodioxole |
| 5-methoxy-6-(prop-2-en-1-yl)-1,3-dioxaindane |
| EN300-6746525 |
| Z2182005509 |
| AKOS040753939 |
Drug Classes (1)
| Class | Description |
|---|
| benzodioxoles | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 39.69
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 39.69 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.73 (4.65) | | Search Engine Demand Index | 53.49 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |